Picture [iito] Männer Ballett 650x80px
Document › Details

Epistem Holdings plc. (12/18/13). "Press Release: Epistem Announces Evaluation of Genedrive by US Department of Defence for Pathogen Detection".

Region Region United States (USA)
Organisations Organisation Epistem Holdings plc
  Group Epistem (Group)
  Organisation 2 US Air Force
  Group United States (govt)
Products Product Genedrive™ molecular device
  Product 2 point-of-care diagnostic device
Person Person Walls, Matthew (EpiStem 200704 CEO)

Epistem Holdings Plc (LSE: EHP), the biotechnology and personalised medicine company, announces today a cooperative agreement with the US Air Force alongside an agreement with Johns Hopkins University - Advanced Physics Laboratory, to undertake the combat (in field use) evaluation of Epistem's Genedrive(R) handheld molecular device for pathogen detection. The agreement will commence immediately and provides Epistem with $0.6m (GBP0.4m) during the initial 6 month phase to develop and evaluate Genedrive(R) for the identification of three known disease pathogens. Successful completion of the initial evaluation phase will secure ongoing investment for the development and potential roll out of the handheld pathogen detection unit for the US Department of Defence.

Preparations for the 2014 launch of the company's first Genedrive(R) disease test in Tuberculosis continue, with progress to resolve the earlier reported software and firmware issues now nearing completion. Whilst unit testing is ongoing, preparations are now being made for the commencement of final stage clinical trials in support of Indian regulatory approval. Plans to undertake clinical trials in 2014 with the Foundation for Innovative New Diagnostics (FIND) have also commenced as a forerunner to securing a World Health Organisation (WHO) recommendation in 2015.

For further details please contact:

Epistem Plc
Matthew Walls: Chief Executive Officer ++44 (0)161 606 7258
John Rylands: Finance Director

Peel Hunt LLP
James Steel ++44 (0)207 418 8900
Oliver Jackson

Walbrook PR
Mike Wort ++44 (0)207 933 8780
Anna Dunphy

Notes for editors

Epistem is a biotechnology and personalised medicine company commercialising its expertise in stem cells in the areas of epithelial (oncology, gastrointestinal and dermatological) and infectious diseases. Epistem develops innovative therapeutics, biomarkers and diagnostics (Genedrive(R) ) alongside contract research services for drug development companies. The Group's core expertise is focused around the regulation of adult stem cells located in epithelial tissue including the gastrointestinal tract, skin, hair follicles, breast and prostate and utilizing novel, proprietary next generation molecular biology for use in personalised medicine.

Record changed: 2016-03-19


Picture ConsulTech GmbH RnD Credit Germany 650x80px

More documents for Epistem (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80

» top